Keyword: Sovaldi

J&J, tiny RNA biotech Arcturus combine for hepatitis B work

by Ben Adams

Thursday, October 19, 2017

Johnson & Johnson has notched a deal with Arcturus Therapeutics to help with its new focus on hepatitis B.

NuCana plans $115M IPO to test retooled chemotherapies

by Nick Paul Taylor

Wednesday, September 6, 2017

The anticipated haul will fund late-phase trials of NuCana’s reformulated cancer candidates, including a version of Eli Lilly’s Gemzar.

Medivir sells Chinese rights to hepatitis C drug to Ascletis

by Nick Paul Taylor

Friday, August 18, 2017

The deal continues the retreat from infectious diseases Medivir began after Gilead and others cornered the hepatitis C market.

Newsummit Biopharma licenses hepatitis C antibody from charity group

by Angus Liu

Wednesday, March 15, 2017

Chinese CRO Newsummit Biopharma has received a license to a hepatitis C antibody from MRC Technology, a medical research charity.

5. Gilead Sciences

by Ben Adams

Gilead Sciences could at one time do no wrong, but then sales of its hep C meds slowed and it hit some major trial setbacks. Now, the biotech faces increasingly loud questions about what its next Big Thing will be.

AbbVie looks to battle Gilead with new hep C data

by Ben Adams

Monday, April 18, 2016

Although a little late to the game, AbbVie is touting impressive cure rates for its new daily hep C combo as it looks to find a bigger wedge in a market dominated by Gilead.

GET THE NEWSLETTER

Subscribe to FierceBiotech to get industry news and updates delivered to your inbox.